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Copyright © 200? JCBN Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to inhibit cancer
growth by inhibiting the activity of cyclooxygenase (COX). However, there is increasing
evidence that the COX-independent pathway may be also involved in the inhibitory effect of
NSAIDs against tumor progression. Tolfenamic acid is a NSAID that exhibits anticancer
activity in pancreatic and colorectal cancer models. In the present study, the anti-tumor effect
of tolfenamic acid in KB human oral cancer cells is investigated. The results showed that
tolfenamic acid does not alter the expression of the COX proteins, but it inhibits cell growth
and induces apoptosis as evidenced by the annexin V positivity, sub-G1 population, nuclear
fragmentation and the cleavage of poly ADP-ribose polymerase. In addition, tolfenamic acid
also leads to a loss of the mitochondrial membrane potential in KB cells. These effects are
related to the activation of p38 mitogen-activated protein kinase (MAPK) pathway. These
results suggest that tolfenamic acid-induced apoptotic cell death inhibits cancer growth by
activating the p38 MAPK pathway for cancer prevention.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) have
traditionally been used as non-prescription analgesics [1]
and can be separated into two classes of NSAIDs: classical
NSAIDs and cyclooxygenase (COX)-2 inhibitors. AllApoptotic Effect of Tolfenamic Acid in KB Cells
Vol. 47, No. 1, 2010
75
classical NSAIDs can inhibit both COX-1 and COX-2 and
selective COX-2 inhibitors bind selectively to COX-2 to
reduce prostaglandin synthesis. It is known that chronic
patients who use NSAIDs can develop gastric ulcers or
gastrointestinal complications. These side effects can be
explained by the inhibition of COX-1 and cause a major
health problem implying that drug efficacy of a COX-2
inhibitor is promising [2].
There is increasing epidemiological and experimental
evidence that these agents have a protective effect in coro-
nary heart disease, as well as certain cancers. Although
many questions are still remained to be answered, there are
numerous evidences suggesting that the enzyme COX-2 is
involved in the development and growth of cancers. Liu
et al. [3] first reported that COX-2 over-expression induces
tumorigenesis by inserting the murine COX-2 gene into rat
mammary gland epithelial cells. Some more evidences
showed that COX-2 is over-expressed in a variety of human
solid cancers compared to normal tissues [4–12]. NSAIDs
can be used as chemopreventive agents because the potential
mechanism of action for NSAIDs is to inhibit COX activity.
Recently, it was reported that NSAIDs have other targets in
addition to COX-2. He et al. [13] reported that the peroxy-
some proliferation activating receptor delta (PPARδ) is also
an APC-regulated target of NSAIDs. In addition, NSAIDs
metabolites can suppress the nuclear factor-κB (NF-κB)
survival signal via I κB kinase α (IκKα) inhibition [14].
These suggest that NSAIDs inhibit tumor growth in a COX-
dependent and -independent pathway. Tolfenamic acid is a
potent, well-tolerated NSAID with a low gastric side effect
and high therapeutic index [15]. It possesses antipyretic and
analgesic activities as evidenced in several animal models
and has shown promising results in long-term treatment of
osteoarthritis, rheumatoid arthritis and migraine [16, 17].
Recently, tolfenamic acid also affects apoptosis in colorectal
cancer cells as well as metastasis and tumorigenesis in
pancreatic cancer models [4, 18, 19].
The p38 mitogen-activated protein kinase (MAPK) has
been reported to be associated with the induction of
apoptosis in several cell types [20]. Moreover, the activation
of p38 MAPK damages the mitochondrial function by
altering the B-Cell Leukemia 2 (Bcl-2) family protein [21].
Therefore, p38 MAPK is a critical signaling pathway in
the complexing signaling events of apoptotic cell death.
However, there are no reports on the p38 MAPK activated
by tolfenamic acid for apoptosis. Therefore, studies in this
laboratory examined the effect and mechanism of tolfenamic
acid on the growth of KB cells.
Materials and Methods
Reagents
The poly ADP-ribose polymerase (PARP) antibody was
obtained from BD PharmingenTM (San Jose, CA). The
antibody for COX-1 and actin was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The COX-2 antibody
was purchased from Cayman (Ann Arbor, MI). The
antibodies for phosphor-p38 and total p38 were supplied by
Cell Signaling Technology (Beverly, MA). SB203580 and
Propidium Iodide were obtained Calbiochem (San Diego,
CA) and RNase A was obtained from Sigma-Aldrich
Korea (Yongin city, Korea). Tolfenamic acid (Fig. 1A) was
purchased from Dae He Chemical Co. (Shihung, Korea).
Cell culture and drug treatment
The KB human oral cancer cells were obtained from the
American Tissue Culture Collection (Manassas, VA) and
cultured at 37°C, in Dulbecco’s modified essential medium
Fig. 1. A, The structure of tolfenamic acid; B, The effect of 50,
75 and 100 µM of tolfenamic acid (one of nonsteroidal
anti-inflammatory drugs (NSAIDs) for 48 h on the
expressions of cyclooxygenase (COX) proteins in KB
cells. Immunoblot detection of the COX-1 and COX-2
proteins in whole cell lysates. C, Immunoblot detection
of COX-2 protein in whole cell lysates treated with
dimethyl sulfoxide (DMSO), 100 µM of tolfenamic acid,
and 60 µM of Celecoxib. Actin was used to normalize
the protein loading from each treatment.J.-H. Kim et al.
J. Clin. Biochem. Nutr.
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(DMEM) containing 5% fetal bovine serum (FBS) and
100 U/ml each of penicillin and streptomycin in a 5% CO2
atmosphere. An equal number of cells were seeded and
allowed to attach. The cells were treated with dimethyl
sulfoxide (DMSO) (0.1%) or tolfenamic acid (50, 75 and
100 μM) diluted in DMEM with 2.5% FBS for 48 h.
Cell proliferation assay
The KB cells were counted to examine the effects of 50,
75 and 100 μM of tolfenamic acid for 48 h on the number of
viable cells. The cell count was carried out using a hemato-
cytometer with trypan blue (0.4%). Each experiment was
performed in triplicate and the results are expressed as the
means ± SD for each treatment group.
MTT Assay
A MTT assay kit (Sigma-Aldrich Korea, St. Louis, MO)
was used to examine the effect of 50, 75 and 100 μM of
tolfenamic acid on cell growth in KB cells. In brief, after
the treatment of tolfenamic acid for 48 h, 20 μl of a MTT
solution (2 mg/ml) was added to each well and the cells
were incubated for 2 h at 37°C. The supernatant was
removed and 100 μl of DMSO was added to each well to
dissolve the water insoluble purple formazan crystals. The
formazan absorbance was measured at 560 nm. All the
measurements were carried out in triplicate. The results
are expressed as the percentages proliferation with respect
to the DMSO-treated cells.
Western blot analysis
The whole cell lysates were extracted using a lysis buffer
and the protein was quantified using the Bradford protein
assay. The protein samples were size-separated by electro-
phoresis on SDS-polyacrylamide gels and the separated
proteins were electroblotted onto nitrocellulose membranes.
The blot was blocked in 5% skim milk for 1 h at room
temperature (RT), and incubated with the primary antibody
overnight at 4°C. Incubation with a HRP-conjugated
secondary antibody was then carried out at RT for 4 h. The
antibody-bound proteins were detected using an ECL
Western blotting analysis system.
FACS Analysis for Sub-G1 DNA Measurement
After treatment with 75 and 100 μM of tolfenamic acid
for 48 h, the detached KB cells were collected and combined
with the adherent cells that had been released by trypsiniza-
tion. The cells were fixed in 70% ethanol overnight at
−20°C. Then, the cells were then subsequently stained with
0.02 mg/ml propidium iodide (PI) and subjected to DNA
content analysis using a FACScan cytometer.
Determination of apoptosis induction using Annexin V-FITC
The induction of apoptosis was determined using the
Annexin V-FITC Apoptosis Detection method. The KB cells
were collected, washed with phosphate buffered saline
(PBS) and assayed for the presence of extracellular phos-
phatidylserine using a conjugated Annexin V-FITC antibody
with propidium iodide (PI). The results were performed
using a FACScan cytometer.
4'-6-diamidino-2-phenylindole (DAPI) staining
The level of cell death was measured by DAPI staining
(Sigma Chemical Co, MO). After the experimental treat-
ment with 75 and 100 μM of tolfenamic acid for 48 h, the
KB cells were harvested by trypsinization and fixed in 4%
paraformaldehyde at RT for 20 min. The cells were resus-
pended in PBS, deposited them on poly-L-lysin-coated
slides, stained with a DAPI solution (2 μg/ml) and viewed
under a fluorescence microscope.
JC-1 assay
The mitochondrial membrane potential was measured
using 3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-
1) (Stratagene, La Jolla, CA). KB cells were exposed to
50, 75 and 100 μM of tolfenamic acid for 48 h and then
incubated with 1X JC-1 at 37°C for 30 min and washed with
PBS (3X). The green cytoplasmic JC-1 fluorescence was
measured using a FACScan cytometer.
Statistical analysis
The statistical significance was assessed using a Student’s
t test. A p value <0.05 compared with the solvent control
was considered statistically significant.
Results
The effect of tolfenamic acid on COXs
Because tolfenamic acid is a NSAID, it was tested to
determine if it affects the expression of COX proteins. KB
cells were incubated in various concentrations (50, 75 and
100 μM) for 48 h, and examined by western blot analysis
(Fig. 1B). Tolfenamic acid did not decrease the levels of
the COX-1 and COX-2 proteins. To confirm that it does not
decrease the level of COX-2 protein, Celecoxib, a specific
COX-2 inhibitor was used. Even though Celecoxib decreased
the level of COX-2 protein, tolfenamic acid did not affect
it (Fig. 1C).
Tolfenamic acid-induced growth inhibitory activity in KB
cells
To examine if tolfenamic acid inhibited KB cell growth,
the KB cells were treated with various concentration of
tolfenamic acid for 48 h and then the morphological changes
were observed by optical microscopy (Fig. 2A). The
tolfenamic acid-treated cells were detached and rounded-up
in a concentration-dependent manner. MTT assay and viableApoptotic Effect of Tolfenamic Acid in KB Cells
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cell counting were performed to investigate the inhibitory
effects of tolfenamic acid (Fig. 2B and C). 50, 75 and
100 μM of tolfenamic acid for 48 h significantly inhibited
the growth of KB cells in a concentration-dependent manner
and the IC50 value of tolfenamic acid in KB cells was
54.9 μM.
Induction of apoptosis by tolfenamic acid in KB cells
To determine if tolfenamic acid induced apoptosis of the
KB cells, the level of poly ADP-ribose polymerase (PARP)
cleavage was examined by Western blot anlaysis (Fig. 2D).
After the tolfenamic acid treatment for 48 h, the cleaved
PARP (85 kDa) was clearly detected in the cells exposed to
75 and 100 μM of tolfenamic acid whereas the cleaved
PARP was not observed in DMSO-treated KB cells. To
confirm the apoptotic activity of tolfenamic acid, other
distinct features of apoptosis (e.g. Annexin V positivity,
sub-G1 population and nuclear fragmentation using DAPI
staining) were examined (Fig. 3). The sub-G1 peak was
not detected in DMSO-treated KB cells. However, 48 h of
exposure to 75 and 100 μM of tolfenamic acid in KB cells
resulted in cell accumulation in the sub-G1 phase in a
concentration-dependent manner. In addition, 75 and 100
μM of tolfenamic acid increased the number of annexin
V-positive KB cells and nuclear fragmented cells when
compared to the DMSO-treated KB cells. This suggests
that apoptotic cell death event contributed to the growth-
inhibitory effect of tolfenamic acid in KB cells.
The depolarization of mitochondrial membrane potential
involved in tolfenamic acid-induced apoptosis
The mitochondrial apoptotic events involved in tolfenamic
acid-mediated apoptosis were assessed by examining the
depolarization of the mitochondrial membrane potentials
(MMPs) (Fig. 4). The results showed that tolfenamic acid
depolarized the KB cell MMP 48 h after treatment in a
concentration-dependent manner.
p38 MAPK pathway involved in tolfenamic acid-driven
apoptosis
The likely involvement of the p38 MAPK pathways in the
signal transduction of apoptosis and mitochondrial damage
in KB cells induced by tolfenamic acid was examined by
measuring the levels of phosphorylation of these protein
kinases. 100 μM of tolfenamic acid activated the p38
pathway (Fig. 5A). Western blot analysis was performed
using specific protein kinase inhibitors, SB203580 (p38
MAPK) to determine if the activation of p38 MAPK are
Fig. 2. The effect of tolfenamic acid on cell growth in KB cells. A, Photomicrographs of KB cells treated with 50, 75 and 100 µM of
tolfenamic acid for 48 h. The KB cells were treated with DMSO (vehicle control) or various concentrations of tolfenamic acid
for 48 h and then observed by optical microscopy. B, The KB cells were treated with DMSO or various concentrations of 50, 75
and 100 µM of tolfenamic acid for 48 h. Cell proliferation was determined using a trypan blue exclusion assay. The points are
the mean ± SD of three independent experiments. *p<0.05 compared to the control group. C, The cell viability of KB cells was
estimated using a MTT assay. The points are the mean ± SD of three independent experiments. *p<0.05 compared to the control
group. D, The apoptotic effect of tolfenamic acid in KB cells. Immunoblot detection of the cleaved poly ADP-ribose
polymerase (PARP) in whole cell lysates. Actin was used to normalize the protein loading from each treatment.J.-H. Kim et al.
J. Clin. Biochem. Nutr.
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involved in tolfenamic acid-induced apoptosis. As expected,
SB203580 decreased the tolfenamic acid-induced PARP
cleavage (Fig. 5B).
Discussion
Tolfenamic acid is widely used to treat headache and
has exhibited fewer gastrointestinal side effects than other
NSAIDs [22]. There is recent evidence suggesting that
tolfenamic acid also affects apoptosis in colorectal cancer
cells as well as metastasis and tumorigenesis in pancreatic
cancer models [4, 18, 19]. Initially, the effect of tolfenamic
acid on COX-1 and COX-2 as tested. The data showed that
COX-1 and COX-2 proteins were not changed by tolfenamic
acid (Fig. 1B) and it is believed that 50, 75 and 100 μM
of tolfenamic acid for 48 h is not related to the inhibition
of COXs in this cell context even though tolfenamic acid is
a NSAID. These results suggest that tolfenamic acid-
induced cell growth inhibition in this study might occur in a
COX-independent manner. The effects of tolfenamic acid on
the growth of KB human cancer cells and the mechanism
underlying these effects were then investigated. Tolfenamic
acid inhibited the growth of KB cells (Fig. 2). Higher
concentration of tolfenamic acid (100 μM) resulted in more
than 70% cell death and detached and rounded-up within
48 h after treatment. In addition, tolfenamic acid induced
apoptosis as evidenced by the increased sub-G1 population,
annexin V positivity, nucleosomal fragmentation and cleaved
PARP suggesting that apoptosis contributed to the inhibitory
effects of tolfenamic acid on the viability of KB cells
(Figs. 2D and 3). These results are in agreement with
previous reports in that tolfenamic acid induces PARP
cleavage in colorectal cancer cells [19] and pancreatic
cancer cells [4].
Mitochondrial damage manifests as an initial hyper-
polarization, followed by a loss of the mitochondrial mem-
brane potential and the release of proteins from the mito-
chondrial intermembrane space such as cytochrome c.
Direct and indirect perturbation of the mitochondria can
activate the apoptotic pathway. Tolfenamic acid signifi-
cantly induced the loss of MMP, suggesting that mito-
chondrial damage is involved in tolfenamic acid-induced
apoptosis (Fig. 4). Several studies have demonstrated that
the p38 MAPK pathway results in the apoptotic pathway
through the loss of MMPs [23–26]. Although several studies
already reported that tolfenamic acid induces apoptosis in
Fig. 3. The effect of tolfenamic acid on apoptotic cell death in KB cells. The KB cells were treated with dimethyl sulfoxide (DMSO) or
various concentrations of 75 and 100 µM of tolfenamic acid for 48 h. A, The sub-G1 fraction was assessed by propidium iodide
(PI) staining and flow cytometry analysis, Bar graph represents two-independent experiments; B, Annexin V-PI staining was
carried out to detect apoptosis, Bar graph represents two-independent experiments; C, Fluorescence microscopy images of
the 4'-6-diamidino-2-phenylindole (DAPI)-stained KB cells showing the concentration-dependent appearance of an apoptotic
morphology in the tolfenamic acid-treated KB cells. White arrows point nuclear condensation and fragmentation.Apoptotic Effect of Tolfenamic Acid in KB Cells
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cancer cell lines, there is no report on the tolfenamic acid-
induced activation of the p38 MAPK signaling pathways
[4, 18, 19, 27]. Accordingly, this study examined the role of
p38 MAPK pathway in tolfenamic acid-induced apoptosis in
KB cells. The results showed that tolfenamic acid-induced
apoptosis is dependent on the p38 MAPK signaling pathway
and plays a key role in inducing apoptotic cell death.
However, 75 μM of tolfenamic acid did not activate p38
MAPK pathway whereas the same concentration does
cleave PARP. This suggests that other mechanism as well as
p38 MAPK may be involved in tolfenamic acid-induced
apoptosis. Recently, Safe’s group reported that specificity
protein 1 (Sp1) is degraded by tolfenamic acid to inhibit
several cancer cell lines including pancreatic cancer [4, 18].
Thus, Sp1 can be another possible molecular target for
tolfenamic acid-induced apoptosis.
In conclusion, this study demonstrated that tolfenamic
acid inhibits KB human cancer cell proliferation by inducing
apoptosis through the depolarization of MMP in a COX-
independent manner. This is associated with the activation
of the p38 MAPK pathway. Therefore, it was concluded that
the apoptotic mechanism of tolfenamic acid in KB cells
might be mediated by a mitochondria-driven apoptotic
pathway through p38 MAPK. Overall, tolfenamic acid may
be a good candidate for cancer treatment.
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